CCP
NTLA icon

Clough Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

Clough Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-42,600
Closed -$600K – 155
2017
Q1 		$600K Buy
+42,600
New +$572K 0.04% 120
2016
Q4 		– Sell
-24,800
Closed -$422K – 192
2016
Q3 		$422K Buy
+24,800
New +$480K 0.02% 155

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clough Capital Partners's NTLA Position: Q2 2017 in Review

Clough Capital Partners sold out of Intellia Therapeutics (NTLA) in Q2 2017, closing a stake of 42,600 shares — an estimated $600K sold.

Clough Capital Partners first reported a position in NTLA in Q3 2016 and held it in 2 quarters. The position peaked at $600K in Q1 2017. 85 funds tracked by Wall St. Rank hold NTLA as of Q2 2017.

  • Clough Capital Partners reported no remaining Intellia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Clough Capital Partners sold 42,600 Intellia Therapeutics shares in Q2 2017, an estimated $600K.
  • Clough Capital Partners first reported a position in Intellia Therapeutics in Q3 2016 and held it in 2 quarters.
  • Clough Capital Partners's Intellia Therapeutics position peaked at $600K in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2017.

Based on Clough Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.